Showing results (91-100 of 4,380) with videos related to

Sort By:
Pageof 438
ACS Medicinal Chemistry Letters|October 15, 2025
Polybromo‑1 Bromodomain Inhibitor Selectivity Is Mediated by a Unique Ligand-Binding PocketRaymundo Nuñez, Karina L Bursch, Savannah J Makowski, et al.
ACS Medicinal Chemistry Letters|October 15, 2025
Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan-Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo EfficacyKaranvir Singh, Atamjit Singh, Arprita Malhan, et al.
ACS Medicinal Chemistry Letters|October 15, 2025
Recent Advancements in 20S Proteasome Enhancement: Degradation of Undruggable TargetsSydney G Cobb, Jetze J Tepe
ACS Medicinal Chemistry Letters|October 15, 2025
Pharmacophore-Based Structure Optimization of S‑Trityl‑l‑Cysteine Derivatives for Cytotoxic Payload ApplicationsTaiki Ichida, Naohisa Ogo, Keisuke Murase, et al.
ACS Medicinal Chemistry Letters|October 15, 2025
Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer TreatmentYouichi Kawakita, Takuto Kojima, Noriyuki Nii, et al.
ACS Medicinal Chemistry Letters|December 18, 2020
Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic MalignanciesVenkateshwar Rao Gummadi, Anima Boruah, Bharathi Raja Ainan, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Identification of Novel Rho-Kinase-II Inhibitors with Vasodilatory ActivitySeema Kesar, Sarvesh Paliwal, Pooja Mishra, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth InhibitionZhenhua Wu, Jean-Simon Suppo, Sarka Tumova, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting RacematesSheila DeWitt, Anthony W Czarnik, Vincent Jacques
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK InhibitorXuejun Zhang, Xijun Sheng, Jie Shen, et al.
Pageof 438